OncoVex News
Most Popular OncoVex Story
OncoVex - 10 promising late-stage cancer drugs
Amgen ($AMGN) made a huge bet on OncoVex in January with the buyout of the drug's Woburn, MA-based developer, BioVex, in a deal worth up to $1 billion. Later this year Amgen expects to see primary Read more...
Latest Headlines
- April 4, 2011
- January 25, 2011
- November 10, 2009
- November 2, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
